IN2014DN08417A - - Google Patents
Info
- Publication number
- IN2014DN08417A IN2014DN08417A IN8417DEN2014A IN2014DN08417A IN 2014DN08417 A IN2014DN08417 A IN 2014DN08417A IN 8417DEN2014 A IN8417DEN2014 A IN 8417DEN2014A IN 2014DN08417 A IN2014DN08417 A IN 2014DN08417A
- Authority
- IN
- India
- Prior art keywords
- formulations
- insulin
- rapid acting
- absorption
- mixing
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 8
- 239000000203 mixture Substances 0.000 abstract 6
- 102000004877 Insulin Human genes 0.000 abstract 4
- 108090001061 Insulin Proteins 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 229940125396 insulin Drugs 0.000 abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 206010022086 Injection site pain Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid ('EDTA') a dissolution/stabilization agent such as citric acid a magnesium salt and optionally additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration while minimizing residence time of the mixture are also described.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624844P | 2012-04-16 | 2012-04-16 | |
| US201261704066P | 2012-09-21 | 2012-09-21 | |
| US13/826,806 US9381247B2 (en) | 2012-04-16 | 2013-03-14 | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| PCT/US2013/036742 WO2013158618A1 (en) | 2012-04-16 | 2013-04-16 | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08417A true IN2014DN08417A (en) | 2015-05-08 |
Family
ID=48326401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8417DEN2014 IN2014DN08417A (en) | 2012-04-16 | 2013-04-16 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9381247B2 (en) |
| EP (2) | EP2838506B1 (en) |
| JP (2) | JP6422855B2 (en) |
| KR (1) | KR101966484B1 (en) |
| CN (1) | CN104394847A (en) |
| AU (1) | AU2013249495B2 (en) |
| CA (1) | CA2869883A1 (en) |
| CY (1) | CY1123825T1 (en) |
| DK (1) | DK2838506T3 (en) |
| ES (1) | ES2854874T3 (en) |
| HK (2) | HK1207577A1 (en) |
| HR (1) | HRP20210417T1 (en) |
| HU (1) | HUE053303T2 (en) |
| IL (1) | IL234987A0 (en) |
| IN (1) | IN2014DN08417A (en) |
| LT (1) | LT2838506T (en) |
| MX (1) | MX2014012245A (en) |
| PL (1) | PL2838506T3 (en) |
| PT (1) | PT2838506T (en) |
| RS (1) | RS61533B1 (en) |
| RU (1) | RU2014145846A (en) |
| SG (1) | SG11201406491PA (en) |
| SI (1) | SI2838506T1 (en) |
| WO (1) | WO2013158618A1 (en) |
| ZA (1) | ZA201407410B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104902922B (en) | 2012-11-13 | 2017-12-12 | 阿道恰公司 | Rapid-acting insulin preparations comprising substituted anionic compounds |
| KR102351111B1 (en) * | 2014-01-13 | 2022-01-14 | 써멀린 다이어비티즈, 엘엘씨 | Rapid action insulin formulations and pharmaceutical delivery systems |
| WO2015120457A1 (en) * | 2014-02-10 | 2015-08-13 | Biodel Inc. | Stabilized ultra-rapid-acting insulin formulations |
| TWI685348B (en) * | 2014-05-08 | 2020-02-21 | 美國禮來大藥廠 | Rapid-acting insulin compositions |
| WO2016007935A2 (en) | 2014-07-10 | 2016-01-14 | Companion Medical, Inc. | Medicine administering system including injection pen and companion device |
| TW201630622A (en) | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | Fast-acting insulin composition |
| KR20170106373A (en) * | 2015-01-20 | 2017-09-20 | 케이스 웨스턴 리저브 유니버시티 | Insulin analogs with selective signaling properties and reduced mitogenesis promotion |
| JO3749B1 (en) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | Fast acting insulin formulations |
| US10864327B2 (en) | 2016-01-29 | 2020-12-15 | Companion Medical, Inc. | Automatic medication delivery tracking |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| JP2019529506A (en) | 2016-09-29 | 2019-10-17 | アレコル リミテッド | New formulation |
| GB201707189D0 (en) * | 2017-05-05 | 2017-06-21 | Arecor Ltd | Novel formulations |
| CN110662551B (en) | 2017-06-01 | 2023-07-18 | 伊莱利利公司 | Rapid-acting insulin composition |
| US11484657B2 (en) | 2017-06-09 | 2022-11-01 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods |
| US11568975B2 (en) | 2017-10-12 | 2023-01-31 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods for dose recommendation and management |
| JP7512203B2 (en) | 2017-12-12 | 2024-07-08 | ビッグフット バイオメディカル インコーポレイテッド | TREATMENT SUPPORT INFORMATION AND/OR TRACKING DEVICE AND ASSOCIATED METHODS AND SYSTEMS - Patent application |
| US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
| US11197964B2 (en) | 2017-12-12 | 2021-12-14 | Bigfoot Biomedical, Inc. | Pen cap for medication injection pen having temperature sensor |
| US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
| US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
| US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
| US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
| US12357562B2 (en) | 2018-04-04 | 2025-07-15 | Arecor Limited | Injection pen system for the delivery of an insulin compound |
| US11664107B2 (en) | 2018-05-08 | 2023-05-30 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods using a prescription-regulated software application |
| US10898653B2 (en) | 2018-05-08 | 2021-01-26 | Companion Medical, Inc. | Intelligent medication delivery systems and methods for dose setting and dispensing monitoring |
| USD893020S1 (en) | 2018-05-11 | 2020-08-11 | Companion Medical, Inc. | Injection pen |
| USD892819S1 (en) | 2018-06-20 | 2020-08-11 | Companion Medical, Inc. | Display screen with graphical user interface |
| US11587663B2 (en) | 2018-06-20 | 2023-02-21 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods for medicine dose calculation and reporting |
| WO2019243627A1 (en) | 2018-06-23 | 2019-12-26 | Adocia | Device for injecting an insulin solution |
| FR3083985A1 (en) | 2018-07-23 | 2020-01-24 | Adocia | DEVICE FOR INJECTING AN INSULIN SOLUTION (S) |
| FR3083984A1 (en) | 2018-07-23 | 2020-01-24 | Adocia | DEVICE FOR INJECTING AN INSULIN SOLUTION (S) |
| US12205699B1 (en) | 2018-10-30 | 2025-01-21 | Bigfoot Biomedical, Inc. | Method of pairing therapy devices using shared secrets, and related systems, methods and devices |
| US11948671B2 (en) | 2019-04-11 | 2024-04-02 | Medtronic Minimed, Inc. | Intelligent accessories for medicine dispensing device |
| CN116847869A (en) * | 2020-10-08 | 2023-10-03 | 美商玛丽莫里斯博士联合有限责任公司 | Methods and compositions for treating and preventing type 1 diabetes |
| US11701473B2 (en) | 2021-06-23 | 2023-07-18 | Medtronic Minimed, Inc. | Reusable injection pens |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196196A (en) | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
| PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DK503386D0 (en) * | 1986-10-20 | 1986-10-20 | Novo Industri As | PEPTIME PREPARATIONS |
| AU4330597A (en) | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
| WO1999034821A1 (en) * | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| US7279457B2 (en) | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
| US20080096800A1 (en) | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| US20080085298A1 (en) | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| EP2543249B1 (en) | 2007-02-17 | 2018-05-23 | President and Fellows of Harvard College | Compositions and method for tissue preservation |
| TWI394580B (en) | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| FR2943538B1 (en) * | 2009-03-27 | 2011-05-20 | Adocia | QUICK ACTION FORMULATION OF RECOMBINANT HUMAN INSULIN |
| CA2805031A1 (en) | 2010-07-07 | 2012-01-12 | Biodel, Inc. | Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin |
-
2013
- 2013-03-14 US US13/826,806 patent/US9381247B2/en active Active
- 2013-04-16 HR HRP20210417TT patent/HRP20210417T1/en unknown
- 2013-04-16 LT LTEP13721441.7T patent/LT2838506T/en unknown
- 2013-04-16 PT PT137214417T patent/PT2838506T/en unknown
- 2013-04-16 EP EP13721441.7A patent/EP2838506B1/en active Active
- 2013-04-16 PL PL13721441T patent/PL2838506T3/en unknown
- 2013-04-16 CA CA2869883A patent/CA2869883A1/en not_active Abandoned
- 2013-04-16 EP EP20215156.9A patent/EP3827813A1/en not_active Withdrawn
- 2013-04-16 JP JP2015505989A patent/JP6422855B2/en active Active
- 2013-04-16 HK HK15108257.4A patent/HK1207577A1/en unknown
- 2013-04-16 HK HK15103911.3A patent/HK1203371A1/en unknown
- 2013-04-16 AU AU2013249495A patent/AU2013249495B2/en active Active
- 2013-04-16 CN CN201380029323.7A patent/CN104394847A/en active Pending
- 2013-04-16 RU RU2014145846A patent/RU2014145846A/en not_active Application Discontinuation
- 2013-04-16 KR KR1020147032221A patent/KR101966484B1/en active Active
- 2013-04-16 MX MX2014012245A patent/MX2014012245A/en unknown
- 2013-04-16 ES ES13721441T patent/ES2854874T3/en active Active
- 2013-04-16 DK DK13721441.7T patent/DK2838506T3/en active
- 2013-04-16 HU HUE13721441A patent/HUE053303T2/en unknown
- 2013-04-16 RS RS20210209A patent/RS61533B1/en unknown
- 2013-04-16 SG SG11201406491PA patent/SG11201406491PA/en unknown
- 2013-04-16 WO PCT/US2013/036742 patent/WO2013158618A1/en not_active Ceased
- 2013-04-16 IN IN8417DEN2014 patent/IN2014DN08417A/en unknown
- 2013-04-16 SI SI201331836T patent/SI2838506T1/en unknown
-
2014
- 2014-10-05 IL IL234987A patent/IL234987A0/en unknown
- 2014-10-13 ZA ZA2014/07410A patent/ZA201407410B/en unknown
-
2018
- 2018-10-16 JP JP2018194834A patent/JP2019023223A/en active Pending
-
2021
- 2021-02-10 CY CY20211100113T patent/CY1123825T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2854874T3 (en) | 2021-09-23 |
| US9381247B2 (en) | 2016-07-05 |
| SG11201406491PA (en) | 2014-11-27 |
| EP2838506A1 (en) | 2015-02-25 |
| CY1123825T1 (en) | 2022-05-27 |
| EP3827813A1 (en) | 2021-06-02 |
| LT2838506T (en) | 2021-03-25 |
| HUE053303T2 (en) | 2021-06-28 |
| EP2838506B1 (en) | 2021-01-06 |
| KR101966484B1 (en) | 2019-04-05 |
| ZA201407410B (en) | 2015-06-24 |
| JP2015512952A (en) | 2015-04-30 |
| HRP20210417T1 (en) | 2021-04-30 |
| CA2869883A1 (en) | 2013-10-24 |
| SI2838506T1 (en) | 2021-02-26 |
| WO2013158618A1 (en) | 2013-10-24 |
| CN104394847A (en) | 2015-03-04 |
| HK1203371A1 (en) | 2015-10-30 |
| MX2014012245A (en) | 2015-06-05 |
| RS61533B1 (en) | 2021-04-29 |
| DK2838506T3 (en) | 2021-01-18 |
| KR20140146209A (en) | 2014-12-24 |
| PT2838506T (en) | 2021-02-23 |
| JP2019023223A (en) | 2019-02-14 |
| HK1207577A1 (en) | 2016-02-05 |
| US20140113856A1 (en) | 2014-04-24 |
| IL234987A0 (en) | 2014-12-31 |
| RU2014145846A (en) | 2016-06-10 |
| AU2013249495B2 (en) | 2016-05-12 |
| PL2838506T3 (en) | 2021-06-28 |
| JP6422855B2 (en) | 2018-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08417A (en) | ||
| MX2010003776A (en) | Rapid acting injectable insulin compositions. | |
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| MX2011009174A (en) | Insulin formulations for rapid uptake. | |
| HRP20251088T1 (en) | USE OF LONG-ACTING GLP-1 PEPTIDES | |
| UA115139C2 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| CO7101246A2 (en) | Carbamate compound and preparation and use thereof | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| EA201690102A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE | |
| MX2009013663A (en) | Solubilized formulation of docetaxel without tween 80. | |
| NZ627274A (en) | Anesthetic compounds and related methods of use | |
| MX2016002881A (en) | Sodium channel modulators for the treatment of pain and diabetes. | |
| IN2012DE00337A (en) | ||
| FI3383385T4 (en) | Melflufen dosage regimens for cancer | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| MX2020014262A (en) | Pharmaceutical composition containing poorly-soluble basic medicine. | |
| PH12018501274A1 (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| IN2014MN02156A (en) | ||
| MX2015010594A (en) | Lipobalanced long chain testosterone esters for oral delivery. | |
| BR112014018426A8 (en) | COMPOSITION AND DEVICE FOR TRANSDERMAL ADMINISTRATION, AND METHOD FOR ADMINISTERING A PROGESTIN | |
| EA201592297A1 (en) | AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS | |
| MX2010002348A (en) | Liquid formulation of g-csf. | |
| MX2016014738A (en) | Tamper resistant immediate release capsule formulation comprising tapentadol. | |
| EA201500128A1 (en) | PEDIATRIC LIQUID COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING NEPATUTANEAN | |
| JO3689B1 (en) | Njectable formulations of paracetamol |